Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C72560
http://purl.obolibrary.org/obo/NCIT_C72560
|
|---|---|
| Preferred Name | Pomalidomide |
| Definitions |
An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis. |
|---|---|
| prefLabel | Pomalidomide
|
| label | Pomalidomide
|
| PDQ_Closed_Trial_Search_ID | 653314
|
| code | C72560
|
| prefixIRI | NCIT:C72560
|
| in_subset |
See more
See less
|
| Display_Name | Pomalidomide
|
| Preferred_Name | Pomalidomide
|
| FDA_UNII_Code | D2UX06XLB5
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C13H11N3O4
|
| Maps_To | Pomalidomide
|
| CAS_Registry | 19171-19-8
|
| NCI_Drug_Dictionary_ID | 653314
|
| Legacy Concept Name | Pomalidomide
|
| PubMedID_Primary_Reference | 16085014
|
| type | |
| ALT_DEFINITION | A substance being studied in the treatment of prostate cancer, multiple myeloma, and other types of cancer. Pomalidomide is a form of the drug thalidomide. It stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. Pomalidomide is a type of angiogenesis inhibitor and a type of immunomodulatory agent.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 653314
|
| Accepted_Therapeutic_Use_For | adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy and Kaposi sarcoma in adult patients who are HIV-negative
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C2347624
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |